• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Consumers

  • Print
  • Share
  • E-mail

Antiretroviral drugs used in the treatment of HIV infection

Drugs Used in the Treatment of HIV Infection

Click on drug brand name for additional information.

Multi-class Combination Products

Brand NameGeneric NameManufacturer Name*Approval DateTime to Approval
Atriplaefavirenz, emtricitabine and tenofovir disoproxil fumarateBristol-Myers Squibb and Gilead Sciences12-July-062.5 months
Compleraemtricitabine, rilpivirine, and tenofovir disoproxil fumarateGilead Sciences10-August-116 months
Stribildelvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarateGilead Sciences27-August-126 months

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Brand NameGeneric NameManufacturer Name*Approval DateTime to Approval
Combivirlamivudine and zidovudineGlaxoSmithKline27-Sep-973.9 months
Emtrivaemtricitabine, FTCGilead Sciences02-Jul-0310 months
Epivirlamivudine, 3TCGlaxoSmithKline17-Nov-954.4 months
Epzicomabacavir and lamivudineGlaxoSmithKline02-Aug-0410 months
Hividzalcitabine, dideoxycytidine, ddC (no longer marketed)Hoffmann-La Roche19-Jun-927.6 months
Retrovirzidovudine, azidothymidine, AZT, ZDVGlaxoSmithKline19-Mar-873.5 months
Trizivirabacavir, zidovudine, and lamivudineGlaxoSmithKline14-Nov-0010.9 months
Truvadatenofovir disoproxil fumarate and emtricitabineGilead Sciences, Inc.02-Aug-045 months
Videx ECenteric coated didanosine, ddI ECBristol Myers-Squibb31-Oct-009 months
Videxdidanosine, dideoxyinosine, ddIBristol Myers-Squibb9-Oct-916 months
Vireadtenofovir disoproxil fumarate, TDFGilead26-Oct-015.9 months
Zeritstavudine, d4TBristol Myers-Squibb24-Jun-945.9 months
Ziagenabacavir sulfate, ABCGlaxoSmithKline17-Dec-985.8 months

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Brand NameGeneric NameManufacturer Name*Approval DateTime to Approval
EdurantrilpivirineTibotec Therapeutics20-May-11

10 months

IntelenceetravirineTibotec Therapeutics18-Jan-08

6 months

Rescriptordelavirdine, DLVPfizer4-Apr-978.7 months
Sustivaefavirenz, EFVBristol Myers-Squibb17-Sep-983.2 months
Viramune 
(Immediate Release)
nevirapine, NVPBoehringer Ingelheim21-Jun-963.9 months
Viramune XR (Extended Release) nevirapine, NVP
 
Boehringer Ingelheim25-Mar-119.9 months

Protease Inhibitors (PIs)

Brand NameGeneric NameManufacturer Name*Approval DateTime to Approval
Ageneraseamprenavir, APV (no longer marketed)GlaxoSmithKline15-Apr-996 months
Aptivustipranavir, TPVBoehringer Ingelheim22-Jun-056 months
Crixivanindinavir, IDV,Merck13-Mar-961.4 months
Fortovasesaquinavir (no longer marketed)Hoffmann-La Roche7-Nov-975.9 months
Invirasesaquinavir mesylate, SQVHoffmann-La Roche6-Dec-953.2 months
Kaletralopinavir and ritonavir, LPV/RTVAbbott Laboratories15-Sep-003.5 months
LexivaFosamprenavir Calcium, FOS-APVGlaxoSmithKline20-Oct-0310 months
Norvirritonavir, RTVAbbott Laboratories1-Mar-962.3 months
PrezistadarunavirTibotec, Inc.23-Jun-066 months
Reyatazatazanavir sulfate, ATVBristol-Myers Squibb20-Jun-036 months
Viraceptnelfinavir mesylate, NFVAgouron Pharmaceuticals14-Mar-972.6 months

Fusion Inhibitors

Brand NameGeneric NameManufacturer NameApproval DateTime to Approval
Fuzeonenfuvirtide, T-20Hoffmann-La Roche & Trimeris13-Mar-036 months

Entry Inhibitors - CCR5 co-receptor antagonist

Brand NameGeneric NameManufacturer NameApproval DateTime to Approval
SelzentrymaravirocPfizer06-August-078 months

HIV integrase strand transfer inhibitors

Brand NameGeneric NameManufacturer NameApproval DateTime to Approval
IsentressraltegravirMerck & Co., Inc.12--Oct-076 months
Tivicay disclaimer icon dolutegravirGlaxoSmithKline13-August-136 months

 

   *manufacturer/sponsor at time of approval

 

Generic drugs used in the Treatment of HIV Infection

Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan (PEPFAR)